A Phase I Study of the Combination of Temsirolimus with Irinotecan for Metastatic Sarcoma

mTOR inhibitors are emerging as important anti-neoplastic agents with a wide range of clinical applications. The topoisomerase I inhibitor irinotecan is a potent DNA damaging drug, with a broad spectrum of anticancer activities. mTOR appears to enhance cancer cell survival following DNA damage, thus...

Descripción completa

Detalles Bibliográficos
Autores principales: Verschraegen, Claire F., Movva, Sujana, Ji, Yongli, Schmit, Berndt, Quinn, Robert H., Liem, Ben, Bocklage, Therese, Shaheen, Monte
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2013
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3730334/
https://www.ncbi.nlm.nih.gov/pubmed/24216984
http://dx.doi.org/10.3390/cancers5020418

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3730334/
https://www.ncbi.nlm.nih.gov/pubmed/24216984
http://dx.doi.org/10.3390/cancers5020418

Ejemplares similares